Report: Medtronic Misfiled More Than 1,000 Infuse Adverse Event Reports
MINNEAPOLIS — An internal study by Medtronic Inc. of off-label use of its Infuse bone graft found more than 1,000 adverse events but the company stopped the study and then misplaced...To view the full article, register now.
Already a subscriber? Click here to view full article